Today I discuss with Vyas Ramanan, of Third Rock Ventures and Maze Therapeutics, the evolution of the field's understanding of genetic modifiers and the role they play in disease, how drug discovery works when attempting to recapitulate protective effects of certain mutations, and how the convergence of certain advances in statistics and genomic sequencing and perturbation tools enable pressure testing of hypotheses at an unprecedented scale.

Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: bit.ly/datapulse-glossary